BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6330837)

  • 21. Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis.
    Macklin GR; Grassly NC; Sutter RW; Mach O; Bandyopadhyay AS; Edmunds WJ; O'Reilly KM
    Lancet Infect Dis; 2019 Oct; 19(10):1121-1128. PubMed ID: 31350192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
    O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
    Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rat immunogenicity assay of inactivated poliovirus.
    Bevilacqua JM; Young L; Chiu SW; Sparkes JD; Kreeftenberg JG
    Dev Biol Stand; 1996; 86():121-7. PubMed ID: 8785941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine-only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants.
    Brickley EB; Wieland-Alter W; Connor RI; Ackerman ME; Boesch AW; Arita M; Weldon WC; O'Ryan MG; Bandyopadhyay AS; Wright PF
    Clin Infect Dis; 2018 Oct; 67(suppl_1):S42-S50. PubMed ID: 30376086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The antibody response of seronegative infants to inactivated poliovirus vaccine of enhanced potency.
    Simoes EA; John TJ
    J Biol Stand; 1986 Apr; 14(2):127-31. PubMed ID: 3020057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antigenic potency of inactivated poliovirus vaccines.
    Moynihan M; Petersen I
    Dev Biol Stand; 1981; 47():129-33. PubMed ID: 6262143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of a new combined inactivated DPT-polio vaccine.
    Drucker J; Soula G; Diallo O; Fabre P
    Dev Biol Stand; 1986; 65():145-51. PubMed ID: 3030861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antigenicity determination of inactivated poliovirus--the micro-neutralization inhibition test].
    Jiang SD; Pye D
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1985 Aug; 7(4):309-12. PubMed ID: 3011295
    [No Abstract]   [Full Text] [Related]  

  • 29. [The vaccine against poliomyelitis, inactivated, concentrated, injectable: analysis of ten years of use in tropical countries].
    Drucker J
    Bull Soc Pathol Exot; 1991; 84(5 Pt 5):866-72. PubMed ID: 1668069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved ELISA test for determination of potency of Inactivated Poliovirus Vaccine (IPV).
    Rezapkin G; Dragunsky E; Chumakov K
    Biologicals; 2005 Mar; 33(1):17-27. PubMed ID: 15713553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
    Doi Y; Abe S; Yamamoto H; Horie H; Ohyama H; Satoh K; Tano Y; Ota Y; Miyazawa M; Wakabayashi K; Hashizume S
    Dev Biol (Basel); 2001; 105():163-9. PubMed ID: 11763324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. sIPV process development for costs reduction.
    Thomassen YE; Bakker WA
    Vaccine; 2015 Aug; 33(35):4307-12. PubMed ID: 25858858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.
    Asturias EJ; Bandyopadhyay AS; Self S; Rivera L; Saez-Llorens X; Lopez E; Melgar M; Gaensbauer JT; Weldon WC; Oberste MS; Borate BR; Gast C; Clemens R; Orenstein W; O'Ryan G M; Jimeno J; Clemens SA; Ward J; Rüttimann R;
    Lancet; 2016 Jul; 388(10040):158-69. PubMed ID: 27212429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses.
    Muller DA; Fernando GJP; Owens NS; Agyei-Yeboah C; Wei JCJ; Depelsenaire ACI; Forster A; Fahey P; Weldon WC; Oberste MS; Young PR; Kendall MAF
    Sci Rep; 2017 Oct; 7(1):12644. PubMed ID: 28974777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis.
    Salk J; van Wezel AL; Stoeckel P; van Steenis G; Schlumberger M; Meyran M; Rey JL; Lapinleimu K; Böttiger M; Cohen H
    Dev Biol Stand; 1981; 47():181-98. PubMed ID: 7194827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination.
    Sutter RW; Pallansch MA; Sawyer LA; Cochi SL; Hadler SC
    Ann N Y Acad Sci; 1995 May; 754():289-99. PubMed ID: 7625665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen- to nineteen-month-old infants.
    Halperin SA; Davies HD; Barreto L; Guasparini R; Meekison W; Humphreys G; Eastwood BJ
    J Pediatr; 1997 Apr; 130(4):525-31. PubMed ID: 9108847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.
    He H; Wang Y; Deng X; Yue C; Tang X; Li Y; Liu Y; Yin Z; Zhang G; Chen Z; Xie S; Wen N; An Z; Chen Z; Wang H
    Lancet Infect Dis; 2020 Sep; 20(9):1071-1079. PubMed ID: 32442523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
    Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
    Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine.
    Moriniere BJ; van Loon FP; Rhodes PH; Klein-Zabban ML; Frank-Senat B; Herrington JE; Pallansch MA; Patriarca PA
    Lancet; 1993 Jun; 341(8860):1545-50. PubMed ID: 8099637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.